Nardi Paolo, Vacirca Sara R, Russo Marco, Colella Dionisio F, Bassano Carlo, Scafuri Antonio, Pellegrino Antonio, Melino Gerry, Ruvolo Giovanni
Division of Cardiac Surgery, Faculty of Medicine and Surgery, Tor Vergata University, Rome, Italy.
Division of Anesthesiology, Faculty of Medicine and Surgery, Tor Vergata University, Rome, Italy.
J Thorac Dis. 2018 Mar;10(3):1490-1499. doi: 10.21037/jtd.2018.03.67.
Myocardial protection techniques during cardiac arrest have been extensively investigated in the clinical setting of coronary revascularization. Fewer studies have been carried out of patients affected by left ventricular hypertrophy, where the choice of type and temperature of cardioplegia remain controversial. We have retrospectively investigated myocardial injury and short-term outcome in patients undergoing aortic valve replacement plus or minus coronary artery bypass grafting with using cold crystalloid cardioplegia (CCC) or warm blood cardioplegia (WBC).
From January 2015 to October 2016, 191 consecutive patients underwent aortic valve replacement plus or minus coronary artery bypass grafting in normothermic cardiopulmonary bypass. Cardiac arrest was obtained with use of intermittent antegrade CCC group (n=32) or WBC group (n=159), according with the choice of the surgeon.
As compared with WBC group, in CCC group creatine-kinase-MB (CK-MB), cardiac troponin I (cTnI), aspartate aminotransferase (AST) release, and their peak levels, were lower during each time points of evaluation, with the greater statistically significant difference at time 0 (P<0.05, for all comparisons). A time 0, CK-MB/CK ratio >10% was 5.9% in CCC group versus 7.8% in WBC group (P<0.0001). At time 0 CK-MB/CK ratio >10% in patients undergoing isolated aortic valve replacement was 6.0% in CCC group versus 8.0% in WBC group (P<0.01). No any difference was found in perioperative myocardial infarction (0% versus 3.8%), postoperative (PO) major complications (15.6% versus 16.4%), in-hospital mortality (3.1% versus 1.3%).
In aortic valve surgery a significant decrease of myocardial enzymes release is observed in favor of CCC, but this difference does not translate into different clinical outcome. However, this study suggests that in presence of cardiac surgical conditions associated with significant left ventricular hypertrophy, i.e., the aortic valve disease, a better myocardial protection can be achieved with the use of a cold rather than a warm cardioplegia. Therefore, CCC can be still safely used.
在冠状动脉血运重建的临床环境中,心脏骤停期间的心肌保护技术已得到广泛研究。针对左心室肥厚患者的研究较少,其中心脏停搏液的类型和温度选择仍存在争议。我们回顾性研究了使用冷晶体心脏停搏液(CCC)或温血心脏停搏液(WBC)进行主动脉瓣置换术加或不加冠状动脉旁路移植术患者的心肌损伤和短期预后。
2015年1月至2016年10月,191例连续患者在常温体外循环下接受主动脉瓣置换术加或不加冠状动脉旁路移植术。根据外科医生的选择,使用间歇性顺行CCC组(n = 32)或WBC组(n = 159)实现心脏骤停。
与WBC组相比,CCC组在每个评估时间点的肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)、天冬氨酸转氨酶(AST)释放及其峰值水平均较低,在时间0时差异具有统计学意义(所有比较P<0.05)。在时间0时,CCC组CK-MB/CK比值>10%为5.9%,而WBC组为7.8%(P<0.0001)。在单纯主动脉瓣置换术患者中,时间0时CCC组CK-MB/CK比值>10%为6.0%,WBC组为8.0%(P<0.01)。围手术期心肌梗死(0%对3.8%)、术后(PO)主要并发症(15.6%对16.4%)、住院死亡率(3.1%对1.3%)均未发现差异。
在主动脉瓣手术中,观察到CCC有利于心肌酶释放显著降低,但这种差异并未转化为不同的临床结局。然而,本研究表明,在存在与显著左心室肥厚相关的心脏手术情况,即主动脉瓣疾病时,使用冷心脏停搏液而非温血心脏停搏液可实现更好的心肌保护。因此,CCC仍可安全使用。